We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Read MoreHide Full Article
Halozyme Therapeutics (HALO - Free Report) reported first-quarter 2025 adjusted earnings of $1.11 per share, which comprehensively beat the Zacks Consensus Estimate of 95 cents. Earnings rose 41% year over year.
Total revenues in the first quarter increased 35% year over year to $264.9 million. Revenues too surpassed the Zacks Consensus Estimate of $239 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
The top-line growth was primarily driven by higher royalty payments from Roche (RHHBY - Free Report) for Phesgo and J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab) as well as an increase in sales of bulk rHuPH20 during the quarter.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme were up 6.5% in after-hours trading on May 6, owing to the better-than-expected results as well as the increased financial outlook for 2025.
Year to date, shares of Halozyme have rallied 24.2% against the industry’s decline of 2.8%.
Image Source: Zacks Investment Research
HALO’s Q1 Results in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $168.2 million in the first quarter, up 39% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo on which it earns royalties. Royalty revenues beat our model estimate of $153.3 million.
Product sales were $78 million in the first quarter, up 33.1% from the year-ago quarter’s level. HALO has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Product sales beat our model estimate of $65.7 million.
Revenues under collaborative agreements were $18.6 million in the first quarter, increasing 11.4% on a year-over-year basis.
Adjusted EBITDA was $162 million in the first quarter, reflecting a 40% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $747.9 million as of March 31, 2025, compared with $596.1 million as of Dec. 31, 2024.
HALO's 2025 Guidance Raised
Owing to increased royalty revenues due to the continued strong growth of JNJ’s Darzalex SC and RHHBY’s Phesgo and the robust growth of VYVGART Hytrulo, the company raised its total revenue guidance for 2025.
Total revenues are now expected in the range of $1.20 billion to $1.28 billion compared with the earlier projection of $1.15 billion to $1.22 billion.
Royalty revenues are now anticipated in the range of $750-$785 million, compared with the previous expectation of $725-$750 million.
Adjusted EBITDA is now expected in the band of $790-$840 million, compared with the earlier expectation of $755-$805 million.
Adjusted earnings are now expected in the range of $5.30-$5.70 per share in 2025 versus the previous projection of $4.95-$5.35 per share.
Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 27.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View
Halozyme Therapeutics (HALO - Free Report) reported first-quarter 2025 adjusted earnings of $1.11 per share, which comprehensively beat the Zacks Consensus Estimate of 95 cents. Earnings rose 41% year over year.
Total revenues in the first quarter increased 35% year over year to $264.9 million. Revenues too surpassed the Zacks Consensus Estimate of $239 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
The top-line growth was primarily driven by higher royalty payments from Roche (RHHBY - Free Report) for Phesgo and J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab) as well as an increase in sales of bulk rHuPH20 during the quarter.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme were up 6.5% in after-hours trading on May 6, owing to the better-than-expected results as well as the increased financial outlook for 2025.
Year to date, shares of Halozyme have rallied 24.2% against the industry’s decline of 2.8%.
Image Source: Zacks Investment Research
HALO’s Q1 Results in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $168.2 million in the first quarter, up 39% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo on which it earns royalties. Royalty revenues beat our model estimate of $153.3 million.
Product sales were $78 million in the first quarter, up 33.1% from the year-ago quarter’s level. HALO has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Product sales beat our model estimate of $65.7 million.
Revenues under collaborative agreements were $18.6 million in the first quarter, increasing 11.4% on a year-over-year basis.
Adjusted EBITDA was $162 million in the first quarter, reflecting a 40% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $747.9 million as of March 31, 2025, compared with $596.1 million as of Dec. 31, 2024.
HALO's 2025 Guidance Raised
Owing to increased royalty revenues due to the continued strong growth of JNJ’s Darzalex SC and RHHBY’s Phesgo and the robust growth of VYVGART Hytrulo, the company raised its total revenue guidance for 2025.
Total revenues are now expected in the range of $1.20 billion to $1.28 billion compared with the earlier projection of $1.15 billion to $1.22 billion.
Royalty revenues are now anticipated in the range of $750-$785 million, compared with the previous expectation of $725-$750 million.
Adjusted EBITDA is now expected in the band of $790-$840 million, compared with the earlier expectation of $755-$805 million.
Adjusted earnings are now expected in the range of $5.30-$5.70 per share in 2025 versus the previous projection of $4.95-$5.35 per share.
Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
HALO's Zacks Rank & Stock to Consider
Halozyme currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ earnings per share have increased from $6.30 to $6.36 for 2025. During the same time, earnings per share estimates for 2026 have increased from $6.85 to $7.14. Year to date, shares of ANIP have rallied 27.2%.
ANIP’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.32%.